Clinical trials: Urological Manifestations
Urinary Incontinence, Stress
Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence
The purposes of this study are to determine whether duloxetine can help subjects with stress urinary incontinence and to see whether the effects of duloxetine can be maintained.
- Trial name
- NCT00190996
- Testing
- Duloxetine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 2,765 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder (OAB)
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
- Trial name
- NCT00507169
- Testing
- SVT-40776
- Sponsor
- Salvat
Healthy
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval
The purpose of this study is to assess the electrocardiogram (ECG) effects of fedovapagon dose administration relative to placebo in healthy adult male and female subjects.
- Trial name
- NCT02537288
- Testing
- Fedovapagon, Moxifloxacin
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Overactive Bladder (OAB)
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Outpatients with at least one dispensing record of any medication will be included in the study. An index date will be assigned to each participant and prescription records for anticholinergics will be used in the study.
- Trial name
- NCT03903094
- Testing
- Non-Interventional
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 6,295,279 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Overactive Bladder
Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects
The goal of this interventional clinical trial is to assess the safety, usability and initial efficacy of Xeomin and Vibe combination (ViXe) compared to placebo + sham in female subjects with idiopathic Overactive Bladder.
- Trial name
- XAVIER (NCT06345677)
- Testing
- ViXe Xombination
- Where
- 8 sites in Portugal
- Volunteers
- 48 people
- Sponsor
- Vensica Therapeutics Ltd.
Urinary Incontinence
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully…
- Trial name
- NCT01852058
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 95 people
- Sponsor
- Allergan
Stress Urinary Incontinence, Sexual Dysfunction
Safety, Efficacy and Usage Compliance of the Silk'n Tightra Device
This is an open label, prospective study aimed to evaluate safety and efficacy of the Silk'n Tightra device for improvement of sexual functioning, vulvovaginal appearance and reduction of SUI.
- Conditions
- Stress Urinary Incontinence, Sexual Dysfunction, Vulvovaginal Atrophy
- Trial name
- NCT03900143
- Testing
- Tightra vaginal device
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Home Skinovations Ltd.
Urgency Frequency, Urinary Urge Incontinence
InterStim Therapy Programming Study
This study assessed the effect of different InterStim rate settings on voiding diary outcomes. Specifically, the study evaluated how 3 different rate settings affected the number of urinary incontinent episodes per day collected…
- Trial name
- NCT01009333
- Testing
- InterStim Therapy at rate 5.2 Hz, InterStim Therapy at rate 14 Hz, InterStim Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Biolen, a novel implant, is intended to deliver an anti-androgen locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects.
- Trial name
- Biolen-PC (NCT04284761)
- Testing
- Bicalutamide implant
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 17 people
- Sponsor
- Alessa Therapeutics Inc.
Urinary Incontinence
Study Evaluating the Efficacy and Safety of Yoni.Fit in Women With Stress Urinary Incontinence
Study to evaluate the safety and effectiveness of Yoni.Fit for the temporary management of stress urinary incontinence (SUI) in women.
- Trial name
- NCT03978741
- Testing
- Yōni.Fit Test Device, Yōni.Fit Comparator Device
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Watkins Conti Products. Inc.
Stress Urinary Incontinence
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
- Trial name
- NCT04829994
- Testing
- Intervention
- Where
- 8 sites in United States, Austria and 4 more
- Volunteers
- 198 people
- Sponsor
- Ethicon, Inc.
Overactive Bladder(OAB)
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers
A randomized, open-label, single-dose, replicate crossover study to compare the pharmacokinetics and safety in healthy adult volunteers following oral administration of JLP-2002
- Trial name
- NCT04914221
- Testing
- JLP-2002, Comparator
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Stress Urinary Incontinence
Autologous Cell Therapy for Female Stress Urinary Incontinence
The Autologous Cell Therapy for Female SUI study is a clinical trial to determine the safety and potential effectiveness of a single dose of 200 million Cook MyoSite Autologous Muscle Derived Cells for treatment of Stress Urinary…
- Trial name
- NCT01008943
- Testing
- Autologous Muscle Derived Cells
- Where
- 2 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Cook MyoSite
Overactive Bladder
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking).
- Trial name
- NCT01868516
- Testing
- dexmecamylamine
- Where
- 125 sites in United States
- Volunteers
- 1,635 people
- Sponsor
- Targacept Inc.
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.
- Trial name
- NCT00575016
- Testing
- botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U), botulinum toxin Type A (200U)
- Where
- 6 sites in Egypt, Greece and 4 more
- Volunteers
- 74 people
- Sponsor
- Allergan
Glomerulonephritis, Membranous
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
The main clinical study will be a randomized, double-blind, placebo-controlled, long term study involving a 100 week treatment period.
- Trial name
- NCT01762852
- Testing
- Belimumab 10 mg
- Where
- 30 sites in United States, Australia and 8 more
- Sponsor
- GlaxoSmithKline
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry.
- Trial name
- NCT00332319
- Testing
- GW679769
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Urinary Incontinence,Stress
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have…
- Trial name
- RESTRAIN-SUI (NCT07202884)
- Testing
- Orforglipron
- Where
- 120 sites in United States, Canada and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company